12:00 AM
 | 
Apr 15, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

ARCHITECT Galectin-3 test regulatory update

BG Medicine said partner Abbott Laboratories (NYSE:ABT, Abbott Park, Ill.) received CE Mark approval for the ARCHITECT Galectin-3 test, an automated version of BG Medicine's BGM Galectin-3 test that is marketed as an aid in assessing the prognosis of patients diagnosed with chronic heart failure (CHF). The test measures a patient's blood level of...

Read the full 257 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >